GeneThera, Inc.

OTCPK:GTHR Stock Report

Market Cap: US$3.5k

GeneThera Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Tony Milici

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure26.8yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure6.5yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Tony Milici's remuneration changed compared to GeneThera's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$681k

Jun 30 2022n/an/a

-US$800k

Mar 31 2022n/an/a

-US$938k

Dec 31 2021US$258kUS$258k

-US$1m

Sep 30 2021n/an/a

-US$898k

Jun 30 2021n/an/a

-US$928k

Mar 31 2021n/an/a

-US$837k

Dec 31 2020US$258kUS$258k

-US$774k

Sep 30 2020n/an/a

-US$853k

Jun 30 2020n/an/a

-US$542k

Mar 31 2020n/an/a

-US$493k

Dec 31 2019US$348kUS$348k

-US$518k

Sep 30 2019n/an/a

-US$3m

Jun 30 2019n/an/a

-US$3m

Mar 31 2019n/an/a

-US$3m

Dec 31 2018US$393kUS$258k

-US$3m

Sep 30 2018n/an/a

-US$1m

Jun 30 2018n/an/a

-US$864k

Mar 31 2018n/an/a

-US$676k

Dec 31 2017US$315kUS$225k

-US$758k

Compensation vs Market: Insufficient data to establish whether Tony's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Tony's compensation with company performance.

CEO

Tony Milici (69 yo)

26.8yrs

Tenure

US$258,000

Compensation

Dr. Antonio Milici, also known as Tony, M.D, Ph D, founded GeneThera, Inc. in 1998. Dr. Milici is President and Chief Scientific Officer of GeneThera Inc., and serves as its Chairman and Chief Executive O...

Board Members

NamePositionTenureCompensationOwnership
Antonio Milici
Founder26.8yrsUS$258.00kno data
Jeremiah Bartley
Director6.5yrsno datano data
Winnie Bartley
Director2.8yrsno datano data

6.5yrs

Average Tenure

69yo

Average Age

Experienced Board: GTHR's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/22 23:53
End of Day Share Price 2024/07/25 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GeneThera, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution